Current approaches of nanomedicines in the market and various stage of clinical translation

Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review provides a snapshot of nanomedicines that have been currently launched or in the clinical trials, which manifests a diversified trend in carrier types, applied indications and mechanisms of action. From the perspective of indications, this article presents an overview of the applications of nanomedicines involving the preven-tion, diagnosis and treatment of various diseases, which include cancer, infections, blood disorders, car-diovascular diseases, immuno-associated diseases and nervous system diseases, etc. Moreover, the review provides some considerations and perspectives in the research and development of nanomedicines to facilitate their translations in clinic. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Automated summary

Compared with traditional drug therapy, nanomedicines have shown intriguing biological features that enhance therapeutic efficiency and reduce toxicity. This review provides an overview of currently launched or in-clinical-trial nanomedicines, highlighting the diversified trends in carrier types, applied indications, and mechanisms of action. Additionally, the review presents the applications of nanomedicines in the prevention, diagnosis, and treatment of various diseases, such as cancer, infections, blood disorders, cardiovascular diseases, immuno-associated diseases, and nervous system diseases. The article also offers considerations and perspectives for the research and development of nanomedicines to facilitate their translation into clinical practice.